SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 5 — Focused Visit (Follow-up) — Duke Kahanamoku

PatientDuke Kahanamoku
Date of birth1959-08-24
IdentifiersMRN HR-ML050-SYN; SSN (made up) 000-50-6847
Document date2026-04-27
AuthorKawika Lindgren-Morrison, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Two-week review, five days after the sick visit. [S]

History of Present Illness

Mr. Kahanamoku returns two weeks after spironolactone was added and five days after his sick visit for vomiting and diarrhea, when his potassium was 5.5 mmol/L. He followed the sick-day card: he held empagliflozin, furosemide, spironolactone and sacubitril-valsartan, took half-dose carvedilol for two days and drank oral rehydration solution. The illness settled after three days, and he restarted all his medicines two days ago. His home weight is 93 kg and steady, he has no swelling, orthopnea or lightheadedness, and he walks a mile on the flat without stopping. He is eager to be back in the ocean and asks how to do it safely. [S]

ElementDetail
Since the sick visitMedicines held for three days, restarted two days ago; no further vomiting or diarrhea
Home weight93 kg, steady
FunctionWalks a mile on the flat; NYHA class II
KCCQ-1266, from 56

Review of Systems

SystemResultFinding
GastrointestinalNegativeNo vomiting or diarrhea since three days ago; eating normally
CardiovascularNegativeNo chest pain, palpitations, ankle swelling or lightheadedness
RespiratoryNegativeNo breathlessness at rest; sleeps flat
MusculoskeletalNegativeNo muscle aches on atorvastatin 80 mg

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Aspirin 81 mg delayed-release oral tablet, one tablet dailyOne tablet dailyOral route2021-06-21activeS
Atorvastatin 40 mg oral tablet, one tablet dailyOne tablet dailyOral route2021-06-21 to 2026-03-16completedS
Atorvastatin 80 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-03-16activeS
Metoprolol tartrate 25 mg oral tablet, one tablet twice dailyOne tablet twice dailyOral route2021-06-21 to 2026-03-30completedS
Lisinopril 10 mg oral tablet, one tablet dailyOne tablet dailyOral route2021-06-21 to 2026-03-30completedS
Furosemide 40 mg oral tablet, one tablet every morningOne tablet every morningOral route2026-03-16 to 2026-04-27completedS
Furosemide 20 mg oral tablet, one tablet every morningOne tablet every morningOral route2026-04-27activeS
Sacubitril 24 mg / valsartan 26 mg oral tablet, one tablet twice daily, first dose 36 hours after the last lisinoprilOne tablet twice dailyOral route2026-03-30 to 2026-09-28completedS
Carvedilol 3.125 mg oral tablet, one tablet twice daily with food, starting the evening after the last metoprolol tartrateOne tablet twice daily with foodOral route2026-03-30 to 2026-04-13completedS
Carvedilol 6.25 mg oral tablet, one tablet twice daily with foodOne tablet twice daily with foodOral route2026-04-13 to 2026-04-27completedS
Carvedilol 12.5 mg oral tablet, one tablet twice daily with foodOne tablet twice daily with foodOral route2026-04-27activeS
Empagliflozin 10 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eating or drinkingOne tablet daily, with sick-day rulesOral route2026-03-30activeS
Spironolactone 25 mg oral tablet, one-half tablet (12.5 mg) dailyOne-half tablet dailyOral route2026-04-13activeS
Ferric carboxymaltose 750 mg (15 mL vial, 50 mg/mL) by intravenous infusion, two doses two weeks apartTwo infusions two weeks apartIntravenous route2026-03-30 to 2026-04-13completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-04-27Body height185cmS
2026-04-27Body weight93kgS
2026-04-27Body mass index (BMI) [Ratio]27.2kg/m2S
2026-04-27Systolic blood pressure112mm[Hg]S
2026-04-27Diastolic blood pressure70mm[Hg]S
2026-04-27Heart rate68/minS
2026-04-27Respiratory rate16/minS
2026-04-27Body temperature36.6CelS
2026-04-27Oxygen saturation in Arterial blood by Pulse oximetry97%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-04-27Sodium [Moles/volume] in Serum or Plasma137mmol/L135-145 mmol/LNormalS
2026-04-27Potassium [Moles/volume] in Serum or Plasma4.8mmol/L3.5-5.1 mmol/LNormalS
2026-04-27Creatinine [Mass/volume] in Serum or Plasma1.2mg/dL0.74-1.35 mg/dLNormalS
2026-04-27Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M67mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-04-27Glucose [Mass/volume] in Serum or Plasma97mg/dL70-99 mg/dLNormalS
2026-04-27Magnesium [Mass/volume] in Serum or Plasma2mg/dL1.6-2.6 mg/dLNormalS
2026-04-27Cholesterol [Mass/volume] in Serum or Plasma130mg/dL<=199 mg/dLNormalS
2026-04-27Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation62mg/dLSecondary-prevention goal below 70 mg/dLNormalS
2026-04-27Cholesterol in HDL [Mass/volume] in Serum or Plasma45mg/dL>=40 mg/dLNormalS
2026-04-27Triglyceride [Mass/volume] in Serum or Plasma115mg/dL<=149 mg/dLNormalS
2026-04-27Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma31U/L7-55 U/LNormalS
2026-04-27Overall summary score [KCCQ-12]66{score}S

Physical Exam

Vital signs recorded on 2026-04-27; see the Vital Signs section. [S]

SystemFinding
GeneralWell; blood pressure 112/70, pulse 68; weight 93.0 kg
Orthostatic vital signsStanding at three minutes 108/68 mmHg without symptoms
NeckJugular venous pressure not raised
CardiovascularRegular rhythm; no S3; apical systolic murmur
ExtremitiesNo edema

Problems

ProblemClinical statusVerificationCodeProvenance
Breathlessness on exertion for six weeks (paddling out, walking uphill, finishing his morning swim), with ankle swelling by evening and tiredness, five years after a heart attack; cause to be determinedresolvedconfirmed R06.09S — Synthetic presenting problem, resolved at the second visit when the echocardiogram and cardiology established heart failure with reduced ejection fraction.
Coronary artery disease with an old anterior myocardial infarction five years ago, treated with medicines; synthetic modern episode linked to the documented heart attack of 1952activeconfirmed I25.2S — Synthetic modern diagnosis; the 1952 heart attack remains D in the history.
Heart failure with reduced ejection fraction from ischemic cardiomyopathy (ejection fraction 30% with a thinned, akinetic anterior wall and apex), NYHA class III at diagnosisactiveconfirmed I50.22S — Synthetic modern diagnosis made at the second visit; no claim that he had heart failure in his lifetime.
Iron deficiency without anemia (ferritin 62 ng/mL, transferrin saturation 16%)activeconfirmed E61.1S — Synthetic finding at the heart failure workup.
Viral gastroenteritis for two days, with volume depletion, potassium 5.5 mmol/L and a rise in creatinine on sacubitril-valsartan, spironolactone, empagliflozin and furosemide; settled with sick-day rulesresolvedconfirmed A08.4S — Synthetic intercurrent problem at an unscheduled visit; it follows from his heart failure medicines and does not echo a documented illness.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationBlood pressure and heart rate (seated and standing)Every visitCompleted today112/70 mmHg, pulse 68; standing 108/68 without symptoms
ExaminationWeight, volume status (jugular venous pressure, edema, lungs) and NYHA classEvery visitCompleted today93.0 kg; jugular venous pressure not raised; no edema; NYHA II
LaboratoryMetabolic panel (sodium, potassium, creatinine and eGFR) and magnesiumOne to two weeks after starting or changing a diuretic, ARNI, MRA or SGLT2 inhibitor; then every three to six monthsCompleted todayTwo weeks after spironolactone and two days after restarting held medicines: sodium 137, potassium 4.8, creatinine 1.20 mg/dL (eGFR 67), magnesium 2.0. The one-to-two-week check after spironolactone was also covered by the sick-visit panel at nine days (potassium 5.5 during volume depletion)
Medication safetyGuideline-directed medical therapy: ARNI, evidence-based beta-blocker, MRA and SGLT2 inhibitor, toward target dosesEvery two weeks during titrationCompleted todayCarvedilol raised today; sacubitril-valsartan increase planned in two weeks by the nurse, with a panel a week later
Medication safetyMRA and ARNI: potassium and kidney function during illnessEvery visitCompleted todaySick-day rules used correctly; potassium back to 4.8
LaboratoryLipid panelFour to twelve weeks after a statin change, then every three to twelve monthsCompleted todaySix weeks after atorvastatin 80 mg: LDL 62 mg/dL, total cholesterol 130, HDL 45, triglycerides 115; ALT 31 U/L
SurveyKCCQ-12 heart failure health statusAt diagnosis, then every three to six monthsCompleted today66, from 56
ImagingEchocardiogramAt diagnosis; repeat after three to six months of optimized therapy for device decisions, or with unexplained changeNot indicatedRepeat after three to six months of optimized therapy
ExaminationPrimary-prevention ICD evaluation (and CRT if QRS is wide)After at least 90 days of optimized therapy, and at least 40 days after a myocardial infarctionDueAfter at least 90 days of optimized therapy
ReferralCardiac rehabilitation for heart failureWhen eligible: ejection fraction 35% or below, NYHA II to IV, six weeks of stable therapy and no procedure in six weeksOrderedProgram booked from late May, when he becomes eligible
Self-managementSelf-care: daily weights, sodium, sick-day rules and symptoms to reportEvery visitCompleted todaySick-day card used well; daily weights; dry weight 93 kg
Self-managementCulturally safe care: ʻohana involvement as he chooses; his own healing practicesEvery visitCompleted todayNo Native Hawaiian practices raised today; offer remains open

Goal progress:

Guideline basis: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022); 2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction (2024); 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); CMID: Clinical Monitoring Intelligence Database, heart failure and ischemic heart disease monographs (2026)

Follow-up: Heart failure nurse call in two weeks to raise sacubitril-valsartan, with a metabolic panel one week later. Cardiac rehabilitation from late May. Annual wellness visit in September; heart failure review in about five months with a repeat echocardiogram. Next scheduled visit 2026-09-14: subsequent annual wellness visit. [S]